Webinar: Electrical Field Stimulation for the Functional Maturation of hiPSC-Cardiomyocytes

Recorded on June 27, 2019

One of the biggest gaps to full utilization of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) is their inherent maturation status. In this webinar, Dr. Xiaoyu Zhang and Dr. T.K. Feaster discuss exciting new data from a novel high-throughput instrument that uses electrical conditioning to achieve functionally mature cardiomyocytes that can be used to assess excitation-contraction coupling and other orthogonal assays.

Watch Now

Attend this webinar to learn about:

  • Principle and protocol for electrical pacing of cardiomyocytes
  • Measurable characteristics of matured cardiomyocytes
  • A new instrument that allows high-throughput maturation
  • Implications for the future of cardiac research (workflow models)

Who should attend:

  • Scientists using human-induced pluripotent stem cell cardiomyocytes
  • Safety/tox assessment, drug discovery, cardiac disease modeling

Presenters

Presenter
Dr. Xiaoyu Zhang

Principal Scientist
ACEA Biosciences – a part of Agilent

Xiaoyu Zhang received her Ph.D. in cell molecular and developmental biology from the University of California, Riverside, USA, and conducted postdoctoral training and research at the Burnham Institute for Medical Research. Dr. Zhang joined ACEA Biosciences in 2011 where she has been leading the FDA CiPA studies, cardiac safety screening program and RTCA Cardio/CardioECR applications development.
Presenter
Dr. T.K. Feaster

Product Manager
Fujifilm Cellular Dynamics

Dr. Feaster received his Ph.D. in Pharmacology in 2015 from Vanderbilt University Medical Center for his work using human-induced pluripotent stem cell-derived cardiomyocytes to investigate cardiac excitation-contraction coupling. Dr. Feaster joined FCDI as a technical application scientist working in the applications group, where he served as the primary support liaison for cardiac products, as well as sharing responsibility for in-lab application development. In 2016, Dr. Feaster moved into a field application scientist role for FCDI’s toxicology and safety pharmacology business unit. Dr. Feaster is currently the product manager for the cardiac portfolio at FCDI.